ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
| 38.23 Delayed Data As of Mar 02 |  +0.26 / +0.68%Today’s Change | 15.64 Today|||52-Week Range 38.50 | +20.41% Year-to-Date |
Latest ACAD News | Press Releases
| 'Mad Money' Lightning Round: Allegiant Travel Good, Spirit Airlines Better Feb 28 / TheStreet.com | Will Allscripts (MDRX) Surprise Earnings Estimates in Q4? - Analyst Blog Feb 24 / Zacks.com |
| Will Epizyme (EPZM) Miss Estimates This Earnings Season? - Analyst Blog Feb 25 / Zacks.com | Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog Feb 23 / Zacks.com |
| Is a Surprise Coming for ACADIA Pharmaceuticals (ACAD) This Earnings Season? - Tale o... Feb 25 / Zacks.com | Will Wright Medical (WMGI) Disappoint Earnings Again in Q4? - Analyst Blog Feb 23 / Zacks.com |
| Merrimack Pharmaceuticals (MACK): A Miss this Earnings? - Analyst Blog Feb 24 / Zacks.com | Can Greatbatch (GB) Keep the Earnings Streak Alive in Q4? - Analyst Blog Feb 20 / Zacks.com |
| Will Aegerion (AEGR) Miss Earnings Estimates This Season? - Analyst Blog Feb 24 / Zacks.com | Ecolab's (ECL) Q4 Earnings: Will it Disappoint Estimates? - Analyst Blog Feb 20 / Zacks.com |
Today’s Trading
| Previous close | 37.97 |
| Today’s open | 38.25 |
| Day’s range | 37.82 - 38.50 |
| Volume | 1,645,986 |
| Average volume (3 months) | 1,323,628 |
| Market cap | $3.8B |
| Dividend yield | -- |
Data as of 4:00pm ET, 03/02/2015
Growth & Valuation
| Earnings growth (last year) | -115.91% |
| Earnings growth (this year) | -14.14% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -89.52% |
| P/E ratio | NM |
| Price/Sales | 25,730.20 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| RCPTReceptos Inc | +0.45 | +0.36% |
| GRFSGrifols SA | -0.95 | -2.90% |
| NBIXNeurocrine Bioscienc... | +1.38 | +3.53% |
| SGENSeattle Genetics Inc | -0.25 | -0.69% |
Data as of 4:00pm ET, 03/02/2015
Financials
| Next reporting date | May 5, 2015 |
| EPS forecast (this quarter) | -$0.26 |
| Annual revenue (last year) | $120.0K |
| Annual profit (last year) | -$92.5M |
| Net profit margin | -77,062.50% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, CEO, Director & CAO Uli Hacksell |
Executive VP, Chief Financial & Business Officer Stephen R. Davis |
Corporate headquarters San Diego, California |
Forecasts
